ArticleCellular and molecular life sciences : CMLS2025
REGγ regulates antiviral response by activating TBK1-IFNβ signaling through degradation of PPP2CB.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Although significant progressions in antiviral studies of IFNβ have been demonstrated, the role of the proteasome in modulating cross-talk between TBK1-IFNβ signaling and viral replication during viral infection is not fully elucidated. Here, we discover that deficiency of REGγ, a proteasome activator, significantly reduces IFNβ production and increases viral replications in mice, leading to increased mortality in virus infection models. Our mechanistic study indicates that REGγ interacts with and degrades the protein phosphatase subunit Protein Phosphatase 2 Catalytic Subunit Beta (PPP2CB). This degradation disrupts the dephosphorylation of TBK1 and its interaction with IRF3, resulting in the activation of IFNβ-mediated antiviral signaling. In response to viral infection, up-regulation of REGγ in macrophages accelerates the degradation of PPP2CB, which increases the activation of TBK1-IRF3-IFNβ axis and thereby restricts viral replications and pathology. Interestingly, IFNβ enhances REGγ expression in viral infection, forming a positive feedback regulatory loop. In conclusion, our work demonstrates that REGγ is a positive modulator of IFNβ signaling during antiviral response, highlighting that this procedure is regulated via REGγ degradation of PPP2CB and provides a new insight into the coordination between antiviral response and proteasome activity. Thus, REGγ-proteasome activity and phosphatase PPP2CB may be potential targets in host defense against viruses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.